Structural Basis for Monoclonal Antibody Therapy for Transthyretin Amyloidosis
The disease of transthyretin (TTR) amyloidosis (ATTR) has been known since the 1960s, and during the past 60 or so years, there has been a sustained period of steady discoveries that have led to the current model of ATTR pathogenesis. More recent research has achieved major advances in both diagnost...
Saved in:
| Main Author: | Avi Chakrabartty |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/17/9/1225 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proteomic Analysis of Serum in Cardiac Transthyretin Amyloidosis: Diagnostic and Prognostic Implications for Biomarker Discovery
by: Joanna Waś, et al.
Published: (2025-07-01) -
Clinical case of hereditary transthyretin amyloidosis
by: N. Spasova, et al.
Published: (2024-12-01) -
A rare presentation of pulmonary transthyretin amyloidosis
by: Marc Assaad, et al.
Published: (2025-01-01) -
Vutrisiran in Transthyretin Amyloidosis
by: Ronald M. Witteles, MD, et al.
Published: (2025-09-01) -
Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data
by: Maximilian Leo Müller, et al.
Published: (2024-07-01)